

## Prognostic Value of IMP3 and Cyclin D1 Expression in Patients with Colorectal Cancer

Salem Youssef Mohamed<sup>\*†</sup>, MD, Abeer Hafez<sup>\*\*</sup>, MD, Amira Elwan<sup>\*\*\*</sup>, MD, Mohamed I Abdelhamid<sup>\*\*\*\*</sup>, MD, Nabila Hassan Ahmed<sup>\*\*\*\*\*</sup>, MD, Bader A Abdelmaksoud<sup>\*\*\*</sup>, MD, Abeer M Abdelbary<sup>\*\*</sup>, MD

<sup>\*</sup>Gastroenterology and Hepatology Unit, Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

<sup>\*\*</sup>Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

<sup>\*\*\*</sup>Clinical Oncology Department, Zagazig University, Zagazig, Egypt

<sup>\*\*\*\*</sup>General Surgery Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

<sup>\*\*\*\*\*</sup>Tropical Medicine Department, Zagazig University, Zagazig, Egypt

Please cite this article as: Mohamed SY, Hafez A, Elwan A, Abdelhamid MI, Ahmed NH, Abdelmaksoud BA, et al. Prognostic value of IMP3 and cyclin D1 expression in patients with colorectal cancer. Middle East J Cancer. 2022;13(1):57-66. doi: 10.30476/mejc.2021.85085.1258.

### Abstract

**Background:** Colorectal cancer (CRC) is known to be the third most frequently diagnosed cancer and the fourth leading cause of cancer death worldwide. In Egypt, colorectal carcinoma is considered the 7<sup>th</sup> prevalent cancer, accounting for 3.47% of male cancers and 3% of female malignancies. A localized CRC can be entirely cured via surgical resection. Metastasis remains the leading cause of cancer mortality. IMP3 is an independent prognostic biomarker that expects metastasis and poor prognosis in CRC. The upregulation of nuclear cyclin D1 plays an essential role in pathogenesis and metastases of CRC. We aimed to investigate the expression of IMP3 and cyclin D1 in colorectal carcinoma and their correlation with other clinicopathological features.

**Method:** In this retrospective cohort study, 80 formalin-fixed and paraffin-embedded blocks of CRC were obtained from the subjects. The immunohistochemical expression of IMP3 and cyclin D1 were examined and found to be correlated with clinical-pathological parameters and the outcome of the patients.

**Results:** Overexpression of IMP3 and cyclin D1 was noted in 68.75% and 56.25%, respectively. IMP3 expression was significantly correlated with tumor grade ( $P < 0.001$ ), tumor, node, and metastases (TNM) stage ( $P = 0.040$ ), and lymphovascular invasion ( $P = 0.005$ ); cyclin D1 was significantly associated with TNM stage ( $P < 0.001$ ), lymph node (LN) metastasis ( $P < 0.001$ ), and distant metastasis (DM) ( $P = 0.004$ ); cyclin D1 was significantly correlated with TNM stage ( $P < 0.001$ ), LN metastasis ( $P < 0.001$ ), and DM ( $P = 0.004$ ).

**Conclusion:** IMP3 and cyclin d1 were associated with poor prognosis in CRC, which makes them attractive targets for anticancer drug development.

**Keywords:** IMP3, Cyclin D1, Colorectal cancer, Recurrence, Survival

### Introduction

Colorectal cancer (CRC) is the third most frequently diagnosed

cancer and the fourth top cause of cancer death worldwide.<sup>1</sup>

In Egypt, colorectal carcinoma is

#### Corresponding Author:

Salem Youssef Mohamed, MD  
Department of Internal  
Medicine, Faculty of Medicine,  
Zagazig University, Zagazig,  
Egypt  
Tel: 01016124371  
Email:  
salemyousefmohamed@gmail.com



**Table 1.** Clinicopathological features, immunohistochemical markers, treatment, and outcome

| All patients (N=80)      |     |       | All patients (N=80)                     |              |       |
|--------------------------|-----|-------|---|--------------|-------|
|                          | No. | %     |   | No.          | %     |
| <b>Characteristics</b>   |     |       | <b>Characteristics</b>                  |              |       |
| <b>Gender</b>            |     |       | <b>Surgery</b>                          |              |       |
| Male                     | 56  | 70%   | No surgery                              | 10           | 12.5% |
| Female                   | 24  | 30%   | Hemicolectomy                           | 51           | 63.7% |
| <b>Age</b>               |     |       | <b>Neoadjuvant treatment (N=69)</b>     |              |       |
| <50 years                | 20  | 25%   | No                                      | 54           | 78.3% |
| ≥50 years                | 60  | 75%   | Chemoradiation                          | 15           | 21.7% |
| <b>Site</b>              |     |       | <b>Adjuvant chemotherapy (N=70)</b>     |              |       |
| Rt colon                 | 18  | 22.5% | No                                      | 10           | 14.3% |
| Lt colon                 | 32  | 40%   | Yes                                     | 60           | 85.7% |
| Transverse               | 8   | 10%   | <b>Chemotherapy for Stage IV (N=10)</b> |              |       |
| Rectum                   | 22  | 27.5% | FOLFOX                                  | 1            | 10%   |
| <b>Gross pattern</b>     |     |       | XELOX                                   | 1            | 10%   |
| Fungating                | 46  | 57.5% | FOLFIRI                                 | 8            | 80%   |
| Annular                  | 10  | 12.5% | <b>Response (N=10)</b>                  |              |       |
| Ulcerative               | 24  | 30%   | PR                                      | 4            | 40%   |
| <b>Tumor size</b>        |     |       | SD                                      | 2            | 20%   |
| ≤5cm                     | 34  | 42.5% | PD                                      | 4            | 40%   |
| >5cm                     | 46  | 57.5% | <b>Follow-up duration (months)</b>      |              |       |
| <b>Pathological type</b> |     |       | Mean±SD                                 | 30.37±7.10   |       |
| Conventional             | 70  | 87.5% | Median (Range)                          | 34 (10 – 36) |       |
| Mucoid                   | 10  | 12.5% | <b>Relapse (N=70)</b>                   |              |       |
| <b>Grade</b>             |     |       | Absent                                  | 30           | 42.9% |
| Grade I                  | 15  | 18.8% | <b>First-line chemotherapy (N=40)</b>   |              |       |
| Grade II                 | 45  | 56.3% | 5fu+leucovorin                          | 4            | 10%   |
| Present                  | 40  | 57.1% | Xeloda                                  | 3            | 7.5%  |
| Grade III                | 20  | 25%   | FOLOFOX                                 | 10           | 25%   |
| <b>LVI</b>               |     |       | XELOX                                   | 20           | 50%   |
| Absent                   | 30  | 37.5% | FOLFIRI                                 | 3            | 7.5%  |
| Present                  | 50  | 62.5% | T4                                      | 12           | 15%   |
| <b>T</b>                 |     |       | <b>Second-line chemotherapy (N=50)</b>  |              |       |
| T1                       | 9   | 11.3% | No                                      | 1            | 2%    |
| T2                       | 20  | 25%   | Xeloda                                  | 1            | 2%    |
| T3                       | 39  | 48.8% | DM                                      |              |       |
| <b>LN</b>                |     |       | Negative                                | 70           | 87.5% |
| Negative                 | 30  | 37.5% | Positive                                | 10           | 12.5% |
| Positive                 | 50  | 62.5% | <b>Third line chemotherapy (N=50)</b>   |              |       |
| FOLOFOX                  | 2   | 4%    | No                                      | 46           | 92%   |
| XELOX                    | 12  | 24%   | Xeloda                                  | 1            | 2%    |
| FOLFIRI                  | 34  | 68%   | FOLFIRI                                 | 3            | 6%    |
| <b>Stage</b>             |     |       | <b>Mortality (N=80)</b>                 |              |       |
| Stage I                  | 12  | 15%   | Alive                                   | 38           | 47.5% |
| Stage II                 | 18  | 22.5% | Died                                    | 42           | 52.5% |
| Stage III                | 40  | 50%   |   |              |       |
| Stage IV                 | 10  | 12.5% |   |              |       |
| <b>Cyclin D1</b>         |     |       |   |              |       |
| Negative                 | 35  | 43.8% |   |              |       |
| Positive                 | 45  | 56.2% |   |              |       |
| <b>IMP</b>               |     |       |   |              |       |
| Negative                 | 25  | 31.2% |   |              |       |
| Positive                 | 55  | 68.8% |   |              |       |

Categorical variables were expressed as number (percentage); Continuous variables were expressed as mean ± SD & median (range); DM: Distant metastasis; LVI: Lymphovascular invasion; APR: Abdominoperineal resection; T: Tumor; Rt: Right; Lt: Left; No.: Number

considered to be the 7<sup>th</sup> prevalent cancer, representing 3.47% of male cancers and 3% of

female malignancies.<sup>2</sup>

Once the disease is localized, the surgical

**Table 2.** Relationship between the clinicopathological features and immunohistochemical staining of cyclin D1 and IMP

| Characteristics          | All patients (N=80) |         | Cyclin D1              |                        | P - value | IMP                        |                            | P - value |
|--------------------------|---------------------|---------|------------------------|------------------------|-----------|----------------------------|----------------------------|-----------|
|                          | No.                 | (%)     | Negative (N=35)<br>No. | Positive (N=45)<br>(%) |           | Negative (N=25)<br>No. (%) | Positive (N=55)<br>No. (%) |           |
| <b>Gender</b>            |                     |         |                        |                        |           |                            |                            |           |
| Male                     | 56                  | (70%)   | 23 (41.1%)             | 33 (58.9%)             | 0.461‡    | 18 (32.1%)                 | 38 (67.9%)                 | 0.792‡    |
| Female                   | 24                  | (30%)   | 12 (50%)               | 12 (50%)               |           | 7 (29.2%)                  | 17 (70.8%)                 |           |
| <b>Age</b>               |                     |         |                        |                        |           |                            |                            |           |
| <50 years                | 20                  | (25%)   | 10 (50%)               | 10 (50%)               | 0.515‡    | 7 (35%)                    | 13 (65%)                   | 0.676‡    |
| ≥50 years                | 60                  | (75%)   | 25 (41.7%)             | 35 (58.3%)             |           | 18 (30%)                   | 42 (70%)                   |           |
| <b>Site</b>              |                     |         |                        |                        |           |                            |                            |           |
| Rt colon                 | 18                  | (22.5%) | 8 (44.4%)              | 10 (55.6%)             | 0.467‡    | 6 (33.3%)                  | 12 (66.7%)                 | 0.784‡    |
| Lt colon                 | 32                  | (40%)   | 15 (46.9%)             | 17 (53.1%)             |           | 11 (34.4%)                 | 21 (65.6%)                 |           |
| Transverse               | 8                   | (10%)   | 5 (62.5%)              | 3 (37.5%)              |           | 3 (37.5%)                  | 5 (62.5%)                  |           |
| Rectum                   | 22                  | (27.5%) | 7 (31.8%)              | 15 (68.2%)             |           | 5 (22.7%)                  | 17 (77.3%)                 |           |
| <b>Gross pattern</b>     |                     |         |                        |                        |           |                            |                            |           |
| Fungating                | 46                  | (57.5%) | 20 (43.5%)             | 26 (56.5%)             | 0.563‡    | 12 (26.1%)                 | 34 (73.9%)                 | 0.324‡    |
| Annular                  | 10                  | (12.5%) | 3 (30%)                | 7 (70%)                |           | 5 (50%)                    | 5 (50%)                    |           |
| Ulcerative               | 24                  | (30%)   | 12 (50%)               | 12 (50%)               |           | 8 (33.3%)                  | 16 (66.7%)                 |           |
| <b>Tumor size</b>        |                     |         |                        |                        |           |                            |                            |           |
| ≤5cm                     | 34                  | (42.5%) | 16 (47.1%)             | 18 (52.9%)             | 0.608‡    | 10 (29.4%)                 | 24 (70.6%)                 | 0.760‡    |
| >5cm                     | 46                  | (57.5%) | 19 (41.3%)             | 27 (58.7%)             |           | 15 (32.6%)                 | 31 (67.4%)                 |           |
| <b>Pathological type</b> |                     |         |                        |                        |           |                            |                            |           |
| Conventional             | 70                  | (87.5%) | 30 (42.9%)             | 40 (57.1%)             | 0.741‡    | 23 (32.9%)                 | 47 (67.1%)                 | 0.494‡    |
| Mucoid                   | 10                  | (12.5%) | 5 (50%)                | 5 (50%)                |           | 2 (20%)                    | 8 (80%)                    |           |
| <b>Grade</b>             |                     |         |                        |                        |           |                            |                            |           |
| Grade I                  | 15                  | (18.8%) | 11 (73.3%)             | 4 (26.7%)              | 0.154§    | 11 (73.3%)                 | 4 (26.7%)                  | <0.001§   |
| Grade II                 | 45                  | (56.3%) | 15 (33.3%)             | 30 (66.7%)             |           | 12 (26.7%)                 | 33 (73.3%)                 |           |
| Grade III                | 20                  | (25%)   | 9 (45%)                | 11 (55%)               |           | 2 (10%)                    | 18 (90%)                   |           |
| <b>LVI</b>               |                     |         |                        |                        |           |                            |                            |           |
| Absent                   | 30                  | (37.5%) | 13 (43.3%)             | 17 (56.7%)             | 0.954‡    | 15 (50%)                   | 15 (50%)                   | 0.005‡    |
| Present                  | 50                  | (62.5%) | 22 (44%)               | 28 (56.0%)             |           | 10 (20%)                   | 40 (80%)                   |           |
| <b>T</b>                 |                     |         |                        |                        |           |                            |                            |           |
| T1                       | 9                   | (11.3%) | 3 (33.3%)              | 6 (66.7%)              | 0.496§    | 3 (33.3%)                  | 6 (66.7%)                  | 0.602§    |
| T2                       | 20                  | (25%)   | 11 (55%)               | 9 (45%)                |           | 9 (45%)                    | 11 (55%)                   |           |
| T3                       | 39                  | (48.8%) | 18 (46.2%)             | 21 (53.8%)             |           | 8 (20.5%)                  | 31 (79.5%)                 |           |
| T4                       | 12                  | (15%)   | 3 (25%)                | 9 (75%)                |           | 5 (41.7%)                  | 7 (58.3%)                  |           |
| <b>LN</b>                |                     |         |                        |                        |           |                            |                            |           |
| Negative                 | 30                  | (37.5%) | 22 (73.3%)             | 8 (26.7%)              | <0.001‡   | 9 (30%)                    | 21 (70%)                   | 0.852‡    |
| Positive                 | 50                  | (62.5%) | 13 (26%)               | 37 (74%)               |           | 16 (32%)                   | 34 (68%)                   |           |
| <b>DM</b>                |                     |         |                        |                        |           |                            |                            |           |
| Negative                 | 70                  | (87.5%) | 35 (50%)               | 35 (50%)               | 0.004‡    | 19 (27.1%)                 | 51 (72.9%)                 | 0.063‡    |
| Positive                 | 10                  | (12.5%) | 0 (0%)                 | 10 (100%)              |           | 6 (60%)                    | 4 (40%)                    |           |
| <b>Stage</b>             |                     |         |                        |                        |           |                            |                            |           |
| Stage I                  | 12                  | (15%)   | 10 (83.3%)             | 2 (16.7%)              | <0.001§   | 6 (50%)                    | 6 (50%)                    | 0.040§    |
| Stage II                 | 18                  | (22.5%) | 12 (66.7%)             | 6 (33.3%)              |           | 3 (16.7%)                  | 15 (83.3%)                 |           |
| Stage III                | 40                  | (50%)   | 13 (32.5%)             | 27 (67.5%)             |           | 10 (25%)                   | 30 (75%)                   |           |
| Stage IV                 | 10                  | (12.5%) | 0 (0%)                 | 10 (100%)              |           | 6 (60%)                    | 4 (40%)                    |           |
| <b>Cyclin D1</b>         |                     |         |                        |                        |           |                            |                            |           |
| Negative                 | 35                  | (43.8%) | 12 (34.3%)             | 23 (65.7%)             | 0.605‡    |                            |                            |           |
| Positive                 | 45                  | (56.2%) | 13 (28.9%)             | 32 (71.1%)             |           |                            |                            |           |
| <b>IMP</b>               |                     |         |                        |                        |           |                            |                            |           |
| Negative                 | 25                  | (31.2%) | 12 (48%)               | 13 (52%)               | 0.605‡    |                            |                            |           |
| Positive                 | 55                  | (68.8%) | 23 (41.8%)             | 32 (58.2%)             |           |                            |                            |           |

Categorical variables were expressed as number (percentage); ‡ Chi-square test; § Chi-square test for trend; P<0.05 is significant; DM: Distant metastasis; LVI: Lymphovascular invasion; T: Tumor; Rt: Right; Lt: left; No.: Number

resection of the primary tumor could be enough for a complete cure. Distant metastasis remains the main reason behind treatment failure and cancer fatality.<sup>3</sup>

CRC commonly metastasizes to the liver as most of the GIT drainage pass to the hepatic portal venous circulation. More than 50% of

patients with CRC have liver metastasis, which is the leading cause of cancer mortality in more than two-thirds of cases.<sup>4</sup>

Insulin-like growth factor (IGF) II mRNA-binding protein 3 (IMP3) is one of the IGF mRNA binding protein (IMP) family members containing IMP1, IMP2, and IMP3.<sup>5</sup>

IGF2 messenger RNA binding protein 3 (IGF2BP3, also known as IMP3) has an essential role in the stabilization and trafficking of RNA, cellular growth, and cell migration during embryogenesis.<sup>6</sup>

A range of malignancies as pancreatic, lung, esophageal, thyroid, and melanomas showed IMP3 expression.<sup>7</sup>

Several studies have suggested that IMP3 promotes tumor cell proliferation, adhesion, and invasion.<sup>5</sup>

Furthermore, it has been shown that IMP3 expression, determined via immunohistochemistry, has prognostic significance in a variety of cancers, including CRC.<sup>8</sup>

Cyclin D1 plays an essential role in the cell cycle as it controls the shift of the cell cycle from phase G1 to S phase through pRb mediation. Cyclin D1/cyclin-dependent kinase (CDK) 4–6 complexes initiate the phosphorylation of pRb and cyclin E/CDK2 complex completes the process in the late G1 phase. Alterations in cyclin and CDK expression result in increased cellular

proliferation and participate in malignancy.<sup>9</sup>

The expression of cyclin D1 is of great importance in colorectal pathogenesis and metastasis.<sup>10</sup>


Thus, we aimed to investigate the expression of IMP3 and cyclin D1 in colorectal carcinoma and their correlation with other clinicopathological features.

## Material and Methods

A retrospective cohort study that includes sections from formalin-fixed and paraffin-embedded samples from 80 CRC patients was enrolled in this work.

The local Ethics Committee of the faculty of medicine, Zagazig University, approved this study (ethics code: ZU-IRB#6352/24-8-2020). Written informed consent was taken from the patients or their relatives.

This work was done in the pathology department in collaboration with internal medicine, surgical, tropical, and clinical oncology groups, and university hospitals from January 2015 to



**Figure 1.** This figure represents the Kaplan Meier plot of the colorectal carcinoma patients (N=80), Left panel: disease-free survival; Right panel: overall survival; (A and D) All the studied patients, (B and E) stratified with cyclin D1 and (C and F) stratified with IMP.

**Table 3.** Relationship between immunohistochemical staining of cyclin D1 and IMP and the outcomes among the studied patients (N=80)

| Outcome            | All patients (N=80)        |                            | Cyclin D1                  |                            | P - value                  | IMP                        |                            | P - value |
|--------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|-----------|
|                    | No. (%)                    |                            | Negative (N=35)<br>No. (%) | Positive (N=45)<br>No. (%) |                            | Negative (N=25)<br>No. (%) | Positive (N=55)<br>No. (%) |           |
| <b>Response</b>    | (N=10)                     |                            |                            | (N=10)                     |                            | (N=6)                      | (N=4)                      |           |
| PR                 | 4 (40%)                    |                            |                            | 4 (40%)                    | -                          | 4 (66.7%)                  | 0 (0%)                     | 0.007‡    |
| SD                 | 2 (20%)                    |                            |                            | 2 (20%)                    |                            | 2 (33.3%)                  | 0 (0%)                     |           |
| PD                 | 4 (40%)                    |                            |                            | 4 (40%)                    |                            | 0 (0%)                     | 4 (100%)                   |           |
| <b>Relapse</b>     | (N=70)                     |                            | (N=35)                     | (N=35)                     |                            | (N=19)                     | (N=51)                     |           |
| Absent             | 30 (42.9%)                 |                            | 21 (60%)                   | 9 (25.7%)                  | 0.004‡                     | 19 (100%)                  | 11 (21.6%)                 | <0.001‡   |
| Present            | 40 (57.1%)                 |                            | 14 (40%)                   | 26 (74.3%)                 |                            | 0 (0%)                     | 40 (78.4%)                 |           |
| <b>DFS</b>         |                            |                            |                            |                            |                            |                            |                            |           |
| Mean DFS (95%CI)   | 20.98 months (17.89-24.07) | 25.65 months (21.42-29.88) | 16.31 months (12.37-20.25) | 0.002†                     | 36 months                  | 15.39 months (12.34-18.44) | <0.001†                    |           |
| Median DFS (95%CI) | 14 months (11.77-16.22)    | NR                         | 10 months (7.83-12.16)     |                            | NR                         | 10 months (10-12)          |                            |           |
| 6month DFS         | 88.5%                      | 94.3%                      | 82.9%                      |                            | 100%                       | 84.3%                      |                            |           |
| 12month DFS        | 51.4%                      | 65.7%                      | 37.1%                      |                            | 100%                       | 33.3%                      |                            |           |
| 24month DFS        | 42.9%                      | 65.7%                      | 25.7%                      |                            | 100%                       | 21.6%                      |                            |           |
| 36month DFS        | 42.9%                      | 60%                        | 25.7%                      |                            | 100%                       | 21.6%                      |                            |           |
| <b>Mortality</b>   | (N=80)                     | (N=35)                     | (N=45)                     |                            | (N=25)                     | (N=55)                     |                            |           |
| Alive              | 38 (47.5%)                 | 23 (65.7%)                 | 15 (33.3%)                 | 0.004‡                     | 22 (88%)                   | 16 (29.1%)                 | <0.001‡                    |           |
| Died               | 42 (52.5%)                 | 12 (34.3%)                 | 30 (66.7%)                 |                            | 3 (12%)                    | 39 (70.9%)                 |                            |           |
| <b>OS</b>          |                            |                            |                            |                            |                            |                            |                            |           |
| Mean OS (95%CI)    | 30.37 months (28.82-31.92) | 32.97 months (31.24-34.69) | 28.35 months (26.12-30.58) | 0.003†                     | 33.92 months (31.64-36.19) | 28.76 months (26.91-30.61) | <0.001†                    |           |
| Median OS (95%CI)  | 34 months                  | NR                         | 28 months (25.37-30.62)    |                            | NR                         | 28 months (25.58-30.41)    |                            |           |
| 12 month OS        | 96.3%                      | 100%                       | 93.3%                      |                            | 100%                       | 94.5%                      |                            |           |
| 24 month OS        | 78.8%                      | 88.6%                      | 71.1%                      |                            | 88%                        | 74.5%                      |                            |           |
| 36 month OS        | 47.5%                      | 65.7%                      | 33.3%                      |                            | 88%                        | 29.1%                      |                            |           |

Continuous variables were expressed as mean (95%CI) and median (95%CI); categorical variables were expressed as number (percentage); NR: Not reached yet; ‡ Chi-square test; † Log-rank analysis; P<0.05 is significant; PR: Partial response; SD: Stable disease; PD: Progressive disease; DFS: Disease-free survival; CI: Confidence interval; OS: Overall survival

June 2019. At the pathology department, the research included sections from formalin-fixed and paraffin-embedded samples from 80 CRC patients' specimens that were sent and processed. The patients' data were collected from their records approved by the local Ethical Committee.

All the participants underwent a proper history and examination. Investigations were performed in the form of lab profile and radiological studies, such as pelviabdominal ultrasonography, chest x-ray, and chest and pelviabdominal computed tomography. Bone scan and PET scan were carried out according to clinical scenarios. All the patients underwent colonoscopic diagnostic biopsy. Chemotherapy protocols were proposed for those with functional performance status and adequate organ function in the form of XELOX, Folfox, and single-agent capecitabine was offered as 1<sup>st</sup> line chemotherapy, while the FOLFIRI regimen was mostly as the 1<sup>st</sup> proposed protocol for metastatic and progressed CRC patients. 15 cases were diagnosed with rectal cancer out of 80

patients who received neoadjuvant chemoradiation. The patients' follow-up was to detect disease recurrence and survival outcome.

### Immunohistochemical staining

We utilized the streptavidin-biotin technique.<sup>11</sup> Paraffin-embedded blocks were cut into four-micron thick sections; deparaffinization was done in a sequence of xylene and rehydration was done in descending grades of alcohol and endogenous peroxidase activity was blocked by placing the part in 0.5% hydrogen peroxide in methanol for 10 min of microwave antigen retrieval.

Primary rabbit polyclonal antibody was directed against IMP3 (Thermo Fisher Scientific/Lab Vision Corporation, Rockford, USA; used in a dilution of 1-100) and rabbit monoclonal anti-Anti-cyclin D1 antibody [SP4] (ab16663) dilution 1:50). Furthermore, diaminobenzidine (DAB), as the chromogen, was added for 30 minutes at room temperature. The secondary antibody was added to sections for 30 minutes. Following the incubation, the reaction



product was observed with diaminobenzidine. Ultimately, the sections were counterstained with Mayer's hematoxylin. The negative controls had the primary antibody replaced by a buffer.

#### *Immunohistochemical evaluation of both markers*

##### For Imp3

Cytoplasmic IMP3 expression was evaluated following the method previously designated in a previous study.<sup>12</sup> The percentage of positively stained cells was assessed via microscopic examination of the whole stained section. We defined positive IMP3 expression, as there was considerable brown cytoplasmic staining in more than 5% of tumor cells, regardless of the staining intensity.


##### For cyclin D1

We recorded the proportion of positive tumor cells (0 = 0 to 1%, 1 = 2 to 25%, 2 = 26 to 50%,

3 = 51 to 75%) and 4 = > 75%. For further statistical analyses, cyclin D1 expression was dichotomized into negative, with no expression, and positive, without any expression, fraction, and intensity.<sup>13</sup>

#### *Statistical analysis*

Continuous variables were expressed as the mean  $\pm$  SD and median (range) and the categorical variables as a number (percentage). Continuous variables were checked for normality using the Shapiro-Wilk test. Independent samples Student's t-test was employed to compare the two groups of normally distributed variables, while the Mann Whitney U test was used for non-normally distributed variables. The percentages of categorical variables were compared with Pearson's Chi-square test or Fisher's exact test once it was appropriate. The trend of changes in



**Figure 2.** This figure shows the IMP3 expression in colon cancer: A) Positive strong cytoplasmic IMP3 expression in moderate differentiated colonic carcinoma (ABC, DAB,  $\times 200$ ); B) Positive strong cytoplasmic IMP3 expression in moderate differentiated colonic carcinoma (ABC, DAB,  $\times 400$ ); C) Positive strong cytoplasmic IMP3 expression in high-grade colonic carcinoma (ABC, DAB,  $\times 400$ ).

the distribution of relative frequencies between ordinal data was analyzed using the Chi-square test for trend. The correlation between immunohistochemical markers was analyzed via Spearman correlation. A  $P$ -value  $<0.05$  was considered to be significant. All the statistics were performed with SPSS 22.

## Results

### Clinicopathological results

We had 80 cases of CRC, 56 (70%) of whom were male and 24 (30%) were female, with age ranges from 39 to 72 years with a median (58). 70 cases were conventional adenocarcinoma and 10 were mucoid carcinoma (Table 1).

### Immunohistochemical results

#### IMP3 Results

IMP3 was expressed in the cytoplasm of cancer cells. In our study, IMP3 was found in 55 (68.75%) cases. IMP3 expression was significantly


correlated with tumor grade ( $P < 0.001$ ), tumor, node, and metastases (TNM) stage ( $P = 0.040$ ), and lymphovascular invasion (LVI) ( $P = 0.005$ ). Meanwhile, we found no significant correlations between IMP3 expression and age, gender, tumor location, and tumor size (Table 2, Figure 2).

#### Cyclin D1 results

Cyclin D1 was detected in the nucleus of tumor cells. Herein, cyclin D1 was expressed in 45 (56.25%) cases; cyclin D1 was significantly correlated with TNM stage ( $P < 0.001$ ), lymph node (LN) metastasis ( $P < 0.001$ ), distant metastasis (DM) ( $P = 0.004$ ). Nevertheless, we found no significant correlations between cyclin D1 expression and age, gender, tumor location, tumor size, and grade (Table 2, Figure 3).

IMP3 positive expressed CRC patients had an inadequate treatment response with  $P = 0.007$  considered to be significant (Table 3).

Cyclin D1 and IMP3 positive expressed



**Figure 3.** This figure shows the cyclin D1 expression in cancer colon: A) Positive moderate nuclear cyclin D1 expression in moderate differentiated colonic carcinoma (ABC, DAB,  $\times 400$ ); B) Positive moderate nuclear cyclin D1 expression in moderate differentiated colonic carcinoma (ABC, DAB,  $\times 400$ ); C) Positive strong nuclear cyclin D1 expression in moderate differentiated colonic carcinoma (ABC, DAB,  $\times 100$ ); D) Positive strong nuclear cyclin D1 expression in high-grade colonic carcinoma (ABC, DAB,  $\times 400$ ).



patients had shown significantly worse 3-year disease-free survival (DFS) ( $P = 0.002$  and  $P < 0.001$ , respectively) (95% confidence interval (CI)) (Table 3, Figure 1A, 1B, and 1C).

Negative cyclin D1 and IMP3 were associated with a better 3-year overall survival (OS) ( $P = 0.003$  and  $P < 0.001$ , respectively) (95% CI) (Table 3, Figure 1D, E, and F).

## Discussion

CRC is believed to be one of the deadliest cancers worldwide. Tumor markers are one of the most important factors, which can detect tumor aggressiveness and subsequently the appropriate method of treatment.

A localized CRC can be thoroughly cured with surgical resection. Metastases remain the leading cause of cancer mortality.<sup>14</sup>

IMP3 is an independent prognostic biomarker that expects metastasis and poor prognosis in CRC.<sup>15</sup>

IMP3 is considered a novel biomarker that could differentiate normal from malignant tissue in a variety of organ systems.<sup>7</sup>

Herein, we had 80 cases of colorectal carcinoma, 15 of whom were GI, 45 were GII, and 20 were GIII. IMP3 was expressed in 55 patients. In the study by Huang et al.,<sup>16</sup> IMP3 was abnormally expressed in 72.3% of tumor cells.<sup>16</sup> However, in the survey conducted by Wei et al., IMP3 was shown in 83.1% of cases. Lochhead et al.<sup>15</sup> observed IMP3 expressed in 35% of CRC cases. This variation in the percentages of expression may be due to the use of different primary antibodies. We found that IMP3 expression was significantly correlated with the grade of the tumor ( $P < 0.001$ ) since the expression increased with grade progression as it was expressed in 26.7% of GI, 73.3% of GII, and 90% of GIII; this is in agreement with the work by Wei et al.<sup>17</sup> who found IMP3 to be significantly correlated with the grade in a resection specimen ( $P = 0.043$ ). Moreover, Lochhead et al.<sup>15</sup> found a significant correlation between Imp3 expression and the degree of the tumor ( $P = 0.0003$ ); This is contrary to the findings of Huang et al.,<sup>16</sup> who failed to find a significant

correlation between IMP3 expression and grade of the tumor ( $P = 0.122$ ).

In this study, we also found a significant correlation between IMP3 expression and TNM stage ( $P < 0.001$ ) and LVI ( $P = 0.005$ ). This is following the findings of Wei et al.,<sup>17</sup> who found a substantial correlation between IMP3 expression and TNM stage ( $P = 0.007$ ), LN metastases ( $P = 0.023$ ), and T classification ( $P = 0.035$ ). This is also in agreement with the study by Yuan et al.,<sup>8</sup> who found a significant correlation between IMP3 expression and high-stage tumor ( $P = 0.0417$ ) and lymph node metastasis ( $P = 0.0232$ ).

In our study, we found no meaningful relationships between IMP3 expression and age, gender, tumor location, and tumor size. The obtained results were similar to those of both Wei et al.<sup>17</sup> and Huang et al.,<sup>16</sup> meanwhile, they were contrary to the results of Yuan et al., who found a significant correlation between IMP3 expression and large tumor size ( $P = 0.0452$ ).<sup>8</sup>

The authors found that cyclin D1 was expressed in 45 (56.25%) cases. However, in the survey by Bahnassy et al.<sup>18</sup> cyclin, D 1 was shown at 68.3%. In addition, in the review performed by Salem et al., it was revealed in 48.3%.<sup>19</sup> We found that cyclin D1 expression was significantly correlated with the TNM stage ( $P < 0.001$ ), LN metastasis ( $P < 0.001$ ), and DM ( $P = 0.004$ ).<sup>19</sup> This is in line with the study by Salem et al.,<sup>19</sup> who found a significant correlation between cyclin D1 expression and the presence of lymph node metastases ( $P = 0.000$ ) and DM ( $P = 0.029$ ). Furthermore, Van Wangenheim et al. proved that cyclin D1 was associated with unlucky clinicopathological features of CRC.<sup>20</sup> However, Al-Maghrabi et al. found no associations between cyclin D1 expression and clinicopathological characteristics, except with LVI.<sup>21</sup> Nevertheless, the results of both Holland et al.<sup>22</sup> and Ogino et al.<sup>23</sup> were contrary to our findings since they reported that cyclin D1 overexpression is associated with a good prognosis; moreover, they found that cyclin D1-expressing tumors are less destructive than tumors with reduced cyclin D1 expression.

In this work, we found no significant



correlations between the expressions of both markers despite the increase in the expression of both markers in the high stage. This may be due to different numbers of positive cases in each pen as IMP3 expressed in 55 cases, yet cyclin D appeared only in 45.

Consistent with our study, positively expressed IMP3 patients showed significantly worse 3 - year-DFS=  $P < 0.001$  and associated with worse 3- year- OS with significance.<sup>8,24</sup> Yang et al. observed worse 5 -year- survival ( $P = 0.0012$ ) in IMP3 positive patients and Li et al., demonstrated poor prognosis and colon cancer progression and poor survival prediction in CRC patients with a positive IMP3 expression in tumor cells ( $P = 0.02$ ).<sup>8,24</sup>

Lochhead et al. indicated that IMP3 was an independent prognostic biomarker, as it predicted metastasis and poor prognostic CRC outcome.<sup>15</sup>

Huang et al. observed that patients with positive IMP3 expression in tumor cells had a more mediocre survival rate in comparison with those with negative IMP3 expression in tumor cells. Meanwhile, they found no statistically significant associations between stromal expression of IMP3 and survival rate and demonstrated reduced survival rates for patients with a stromal expression of IMP3 ( $P = 0.06$ ).<sup>16</sup>

Salem et al. reported worse 3-year DFS and OS with significance  $P < 0.001$  and  $P < 0.003$ , respectively, in positive cyclin D1 expression, which is utterly consistent with our results regarding cyclin D1; we also demonstrated worse 3-year- DFS and OS with significance  $P = 0.002$  and  $P = 0.003$ , respectively.<sup>19</sup>

Bahnassy et al.<sup>18</sup> and Maeda et al.<sup>27</sup> observed that cyclin D1 overexpression is associated with poor prognosis,<sup>8,9</sup> yet Wangefjord et al.<sup>13</sup> disagreed with it since they found that cyclin D1 expression was associated with a more favorable outcome for CRC male patients, but not for female; this may be due to the larger sample size of the studied patients and different patient characteristics.<sup>13</sup>

In a meta-analysis, which investigated cyclin D1 expression significance among Asian and non-Asian CRC patients, Li et al. showed that high cyclin D1 overexpression was associated with

poor OS in 21 studies and associated with worse DFS in 10 studies.<sup>24</sup>

The present research is in agreement with other investigators who demonstrated that the multi-disciplinary expansion in the use of preoperative chemotherapy, radiation, and target therapy advances are in favor of disease recurrence reduction and high-risk disease survival benefits in positive expressed IMP3.<sup>25,26</sup>

The limitations of this work were the small sample size. Furthermore, serial estimation of IMP3 after treatment was not done. Therefore, we could recommend further studies with larger sample sizes for studying IMP3 in diagnostic biopsy as well as after management for further clarification of more beneficial justifications of treatment strategies.

## Conclusion

IMP3 and cyclin D1 were associated with poor prognosis in the CRC; accordingly, they could be considered as targets for anticancer drug development.

## Conflicts of Interest

None declared.

## References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin.* 2018;68(1):7-30. doi:10.3322/caac.21442 .
2. Metwally IH, Shetiwy M, Elalfy AF, Abouzid A, Saleh SS, Hamdy M. Epidemiology, and survival of colon cancer among Egyptians: a retrospective study. *J Coloproctol (Rio J).* 2018;38(1):24-9. doi: 10.1016/j.jcol.2017.09.418.
3. Isella C, Terrasi A, Bellomo SE, Petti C, Galatola G, Muratore A, et al. Stromal contribution to the colorectal cancer transcriptome. *Nat Genet.* 2015;47(4):312-9. doi:10.1038/ng.3224.
4. House MG, Kemeny NE, Gonen M, Fong Y, Allen PJ, Paty PB, et al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. *Ann Surg.* 2011;254(6):851-6. doi:10.1097/SLA.0b013e31822f4f88.
5. Bell JL, Wachter K, Muhleck B, Pazaitis N, Kohn M, Lederer M, et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? *Cell Mol Life Sci.*

- 2013;70(15):2657-75. doi:10.1007/s00018-012-1186-z.
6. Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. *Mech Dev.* 1999;88(1):95-9. doi:10.1016/s0925-4773(99)00160-4.
  7. Findeis-Hosey JJ, Xu H. Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer. *Biotech Histochem.* 2012;87(1):24-9. doi:10.3109/10520295.2011.591831.
  8. Yuan RH, Wang CC, Chou CC, Chang KJ, Lee PH, Jeng YM, et al. Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. *Ann Surg Oncol.* 2009; 16:1711-9. doi: 10.1245/s10434-009-0446-0.
  9. Yasui M, Yamamoto H, Ngan CY, Damdinsuren B, Sugita Y, Fukunaga H, et al. Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization. *Clin Cancer Res.* 2006;12(15): 4720-9. doi: 10.1158/1078-0432.ccr-06-0614.
  10. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. *Mol Cancer.* 2007;6:24. doi:10.1186/1476-4598-6-24.
  11. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. *J Histochem Cytochem.* 1981;29(4):577-80. doi:10.1177/29.4.6166661.
  12. Chisté M, Alexis J, Recine M. IMP3 expression in serous tumors of the ovary. *Appl Immunohistochem Mol Morphol.* 2014;22(9):658-62. doi:10.1097/PAI.0000000000000021.
  13. Wangefjord S, Manjer J, Gaber A, Nodin B, Eberhard J, Jirstrom K. Cyclin D1 expression in colorectal cancer is a favorable prognostic factor in men but not in women in a prospective, population-based cohort study. *Biol Sex Differ.* 2011;2:10. doi:10.1186/2042-6410-2-10.
  14. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin.* 2015;65:87-108. doi: 10.3322/caac.21262.
  15. Lochhead P, Imamura Y, Morikawa T, Kuchiba A, Yamauchi M, Liao X, et al. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavorable prognosis in colorectal cancer. *Eur J Cancer.* 2012;48: 3405-13. doi: 10.1016/j.ejca.2012.06.021.
  16. Huang X, Wei Q, Liu J, Niu H, Xiao G, Liu L. Analysis of IMP3 expression in primary tumor and stromal cells in patients with colorectal cancer. *Oncol Lett.* 2017;14(6):7304-10. doi:10.3892/ol.2017.7161.
  17. Wei Q, Huang X, Fu B, Liu J, Zhong L, Yang Q, et al. IMP3 expression in biopsy specimens of colorectal cancer predicts lymph node metastasis and TNM stage. *Int J Clin Exp Pathol.* 2015;8(9):11024-32. doi: 10.3892/or.2017.6072.
  18. Bahnassy AA, Zekri AR, El-Houssini S, El-Shehaby AM, Mahmoud MR, Abdallah S, et al. Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. *BMC Gastroenterol.* 2004;4:22. doi:10.1186/1471-230X-4-22.
  19. Salem AM, Elfeky MA, Nawar N, Alattar AZ, Elekiabi OA, Elaidy MM. Prognostic value of combined; cox-2, cyclin D1 and P21 expression in colorectal cancer (CRC) patients: An immunohistochemical study. *Open J Pathol.* 2018;8(3):106-21. doi:10.4236/ojpathology.2018.83013.
  20. Von Stockmar-Von Wangenheim CA, Mönig SP, Schneider PM, Landsberg S, Drebber U, Hölscher AH, et al. p16, cyclin D1 and Rb expression in colorectal carcinomas: Correlations with clinicopathological parameters and prognosis. *Mol Med Rep.* 2008;1(1):27-32. doi:10.3892/mmr.1.1.27.
  21. Al-Maghrabi J, Mufti S, Gomaa W, Buhmeida A, Al-Qahtani M, Al-Ahwal M. Immunoeexpression of cyclin D1 in colorectal carcinomas is not correlated with survival outcome. *J Microsc Ultrastruct.* 2015;3(2):62-7. doi: 10.1016/j.jmau.2015.01.001.
  22. Holland TA, Elder J, McCloud JM, Hall C, Deakin M, Fryer AA, et al. Subcellular localization of cyclin D1 protein in colorectal tumors is associated with p21(WAF1/CIP1) expression and correlates with patient survival. *Int J Cancer.* 2001;95(5):302-6. doi:10.1002/1097-0215(20010920)95:5<302::aid-ijc1052>3.0.co;2-#.
  23. Ogino S, Nosho K, Irahara N, Kure S, Shima K, Baba Y, et al. A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. *Clin Cancer Res.* 2009;15(13):4431-8. doi:10.1158/1078-0432.CCR-08-3330.
  24. Li D, Yan D, Tang H, Zhou C, Fan J, Li S, et al. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. *Ann Surg Oncol.* 2009;16(12):3499-506. doi:10.1245/s10434-009-0648-5.
  25. van de Velde CJ, Aristei C, Boelens PG, Beets Tan RG, Blomqvist L, Borrás JM, et al. EURECCA colorectal: Multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. *Eur J Cancer.* 2013;49(13):2784-90. doi:10.1016/j.ejca.2013.04.032.
  26. Ahmed S, Johnson K, Ahmed O, Iqbal N. Advances in the management of colorectal cancer: From biology to treatment. *Int J Colorectal Dis.* 2014; 29: 1031-42. doi:10.1007/s00384-014-1928-5.